Global Neurogenic Orthostatic Hypotension Market Size to Exceed USD 855.0 Million By 2035 | CAGR of 7.08%
Category: HealthcareGlobal Neurogenic Orthostatic Hypotension Market Size to Exceed USD 855.0 Million By 2035
According to a research report published by Spherical Insights & Consulting, The Global Neurogenic Orthostatic Hypotension Market Size is expected to Grow from USD 403.0 Million in 2024 to USD 855.0 Million by 2035, at a CAGR of 7.08% during the forecast period 2025-2035.
Get more details on this report -
Browse 210 Market Data Tables And 45 Figures Spread Through 190 Pages and In-Depth TOC On the" Global Neurogenic Orthostatic Hypotension Market Size, Share, and COVID-19 Impact Analysis, By Type (Norepinephrine Reuptake Inhibitors and Adrenergic Medications), By Application (Clinic and Hospital), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035. "Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/neurogenic-orthostatic-hypotension-market
The Neurogenic Orthostatic Hypotension Market Size refers to the industry encompassing the treatment, diagnosis, and management of solutions for the neurogenic orthostatic hypotension condition, which is a form of low blood pressure upon standing caused by autonomic nervous system dysfunction. Neurogenic orthostatic hypotension is the condition characterized by a fall in systolic blood pressure (SBP) of >=20mmHg or diastolic blood pressure (DBP) of >=10 mmHg, within 3 minutes of standing. The condition is commonly found in elderly patients, with is estimated incidence of 233 per 100,000 patients. There is an increasing research on optimizing drug effects for neurogenic orthostatic hypotension, which is providing an opportunity in the neurogenic orthostatic hypotension market. A prevalence of neurogenic orthostatic hypotension, with an increased prevalence of Parkinson’s disease, is significantly driving the market demand. The growing initiative programs for building awareness about nervous system disorders are contributing to propel the market. Further, advancement in treatment approaches, including the use of pyridostigmine and non-pharmacological approaches combined with drug treatment, is propelling the market growth. On the contrary, the potential side effects and safety concerns related to treatment, as well as inadequate training & stringent regulations related to the approval process, are challenging the market.
The norepinephrine reuptake inhibitors segment dominated the market with the largest share of about 60.0% in 2024 and is projected to grow at a substantial CAGR during the forecast period.
Based on the treatment, the neurogenic orthostatic hypotension market is divided into norepinephrine reuptake inhibitors and adrenergic medications. Among these, the norepinephrine reuptake inhibitors segment dominated the market with the largest share of about 60.0% in 2024 and is projected to grow at a substantial CAGR during the forecast period. Norepinephrine reuptake inhibitors (NRIs) have proven to reduce symptoms of neurogenic orthostatic hypotension on a single administration of selective NRI atomoxetine. Ongoing investigation of NRI drugs for treating symptoms related to neurogenic orthostatic hypotension is anticipated to drive the market.
Get more details on this report -
The hospital segment accounted for the largest market share of about 50% in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period.
Based on the application, the neurogenic orthostatic hypotension market is divided into clinic and hospital. Among these, the hospital segment accounted for the largest market share of about 50% in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. Neurogenic orthostatic hypotension is a common cause of hospitalizations, accounting for 80,000 hospitalizations every year in the U.S. The presence of advanced medical equipment and specialized staff in the hospital is responsible for driving the market.
North America is expected to hold the majority share of the global neurogenic orthostatic hypotension market during the forecast period.
North America is expected to hold the majority share of about 38%-47% in the global neurogenic orthostatic hypotension market during the forecast period. The United States is dominating the North America neurogenic orthostatic hypotension market with a major share in 2024, owing to the increased pharmaceutical spending, advanced healthcare accessibility, and upsurging awareness regarding the condition. An increasing investigation by the biopharmaceutical companies in drugs for neurogenic orthostatic hypotension is driving the market for neurogenic orthostatic hypotension. Further, the ongoing study on developing therapeutic strategies and diagnostic tests is contributing to propel market growth.
Asia Pacific is anticipated to grow at the fastest pace of 7.8-8.0% CAGR in the global neurogenic orthostatic hypotension market during the forecast period. China and Japan are leading the Asia Pacific region in the neurogenic orthostatic hypotension market, accounting for 38% and 19.8% share, respectively. This is attributed to the increasing innovation in targeting prevalent chronic conditions as well as Japan’s increasing ageing demographic, which are responsible factors for driving the development of novel dosing technologies. An increasing prevalence of comorbidities like diabetes and Parkinson’s, along with the rapid urbanization and lifestyle changes, is responsible for propelling the neurogenic orthostatic hypotension market.
Major vendors in the global neurogenic orthostatic hypotension market are Lundbeck, Chelsea Therapeutics, Northera Pharmaceuticals, Theravance Biopharma, Sumitomo Pharmaceuticals, and Shire PLC, and Others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Key Market Development
- In October 2025, Theravance Biopharma, Inc. announced the launch of “Power in the Periphery”, a new disease education campaign for healthcare professionals (HCPs) to raise awareness and deepen scientific understanding of the pathophysiology underlying neurogenic orthostatic hypotension (nOH) associated with Multiple System Atrophy (MSA).
- In August 2025, Theravance Biopharma, Inc. announced the completion of enrollment in the open-label portion of its pivotal Phase 3 CYPRESS study in enrollment in the open-label portion of its pivotal Phase 3 CYPRESS study in patients with symptomatic neurogenic orthostatic hypotension (nOH) due to multiple system atrophy (MSA), a rare and progressive neurodegenerative disorder.
Market Segment
This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Neurogenic Orthostatic Hypotension market based on the below-mentioned segments:
Global Neurogenic Orthostatic Hypotension Market, By Type
- Norepinephrine Reuptake Inhibitors
- Adrenergic Medications
Global Neurogenic Orthostatic Hypotension Market, By Application
- Clinic
- Hospital
Global Neurogenic Orthostatic Hypotension Market, By Regional Analysis
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?